BioPharma Dive - Latest News

AbbVie stakes $335M on a startup’s RNAi drugs

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer. 

May 15, 2025 - 16:24
 0
AbbVie stakes $335M on a startup’s RNAi drugs

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer. 

Read More

Tags:

Previous Article

Sanofi to pour more than $20B into US drug research and manufacturing

Next Article

STAT+: An RFK Jr. doubleheader and a very long Medicaid markup

Related Posts

Deerfield secures more than $600M for its next biotech venture fund

Deerfield secures more than $600M for its next biotech ...

May 5, 2025  0

Galapagos backtracks on planned split

Galapagos backtracks on planned split

May 13, 2025  0

Stopping a ‘moral obscenity’: Senate Judiciary Committee expresses support for PBM reform

Stopping a ‘moral obscenity’: Senate Judiciary Committe...

May 15, 2025  0